DermaSys for erectile dysfunction
DermaSys is in clinical development for treating erectile dysfunction (ED), which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. ED is very common, particularly in men over the age of 40 years. It can be caused by any number of physical and psychological factors. Any abnormality involving the nervous, circulatory or hormonal systems, whether due to medication or disease, may affect the ability to develop and sustain an erection. Although ED is a benign disorder, it may affect physical and psychosocial health and may have a significant impact on the quality of life of sufferers and their partners.
Topsalysin for benign prostatic hyperplasia
Benign prostatic hyperplasia (BPH) is a medical term that is used to describe enlargement of the prostate gland. It is not a cancer and is usually not a serious threat to health if well-treated. Most males aged 50 years and above will develop BPH. As the prostate gets bigger, it can place pressure on the …
AQUABEAM® aquablation system for benign prostate hyperplasia
The AquaBeam® system has been developed to treat enlarged prostate glands in men. The prostate is a small gland involved in the production of semen which can enlarge and cause men aged over 50 to have problems urinating. Medicines used to shrink the prostate do not always work, and surgery is then used to cut …
SpaceOAR® perirectal spacing system for prostate cancer radiation
The SpaceOAR® system is an injectable degradable hydrogel developed by Augmenix Inc. and distributed by Oncology Systems Limited, to temporarily position the anterior rectal wall away from the prostate during radiation therapy for prostate cancer. By creating this space, the SpaceOAR® system intends to reduce the radiation dose delivered to the anterior rectum.
ProUroScan™ for imaging abnormalities of the prostate
The ProUroScan™ Imaging System is designed to produce an image of the prostate as an aid in visualising and documenting abnormalities that have been detected by a digital rectal examination. It is being developed by ProUroCare Medical Inc.
REVIEW – New and emerging point of care tests for sexually transmitted infections
The number of diagnoses of sexually transmitted infections (STIs) made at genitourinary medicine (GUM) clinics in the United Kingdom (UK) has increased year on year for at least the last 10 years. Access to sexual health services and STI testing practice are variable across the country. Only a handful of point of care tests (POCTs) …